Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges) (Login Or Register)
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Hi all, my son also has psoriasis, he is 11 and has suffered with this condition for two yrs, he has had numerous creams that haven't worked and now is about to embark on methotrexate, I know this works well and I am familiar with it having used it previously my self, would love to hear your thoughts, x
Posted by: Fred - Thu-16-05-2013 11:30 AM
- No Replies
More Men are offered Biological Treatments for psoriasis than Women. Is it sex discrimination, or is there another reason? This survey from researchers at Sweden's Umeå University thinks it has found the answer.
Moderate to severe psoriasis, once regarded as merely a skin disease, is today seen as an inflammatory systemic disease. The sex ratio of the prevalence of psoriasis is balanced. In recent years several reports have documented that men receive more systemic or UV treatment than women, and different hypotheses were made. In PsoReg, the national registry for systemic treatment of psoriasis in Sweden, we have, like other European registries, observed a predominance of men (59%), especially of men treated with biologics (63%). Biologics are a relatively new group of very effective but high-priced drugs. The objective of this study was to analyse if women are discriminated by not having the same access to the high-priced biologics.
Population based cohort study using data from a nationwide quality register of psoriasis patients.
2294 patients with moderate to severe psoriasis receiving systemic treatment from a specialist in dermatology.
Main Outcome Measures:
Time to initiation of biologic treatment. A multiple Cox proportional hazard’s regression was performed, with time to initiating a biologic treatment as the outcome in order to assess the independent role of the patient’s sex in initiating such therapy. The psoriasis severity was defined as a time-varying variable.
Men had more severe psoriasis than women according to the Psoriasis Area and Severity Index (PASI), regardless of age at enrolment, and throughout the study period. The analysis in the multiple Cox regression show that age, psoriasis severity and psoriasis arthropathy were relevant factors for initiating biologic therapy, whereas sex is not.
Although as many women as men are believed to suffer from psoriasis, men seem to be more severely affected by psoriasis. The asymmetry in allocation of biologic therapy thereby probably reflects the differing disease activity between the sexes, and is not a discrimination against women per se.
Posted by: Fred - Wed-15-05-2013 13:41 PM
- No Replies
Are you single and looking for love? Do you have psoriasis? Do you want to meet the person of your dreams?
‘betty’ are making a third run of the romantic, insightful and acclaimed documentary series The Undateables for Channel 4.
Once again they will be following people with a variety of conditions through the highs and lows of their quest to find love. As with both previous acclaimed series they will explore and challenge some of the issues and barriers that are faced.
They are very interested to hear from you if you suffer from psoriasis and feels this affects your search for love.
If you are interested in taking part please get in touch on 020 7290 0223 or email them at firstname.lastname@example.org
Please mention Psoriasis Club, and if you do take part please add to this thread.
It's that time of year again when my psoriasis gets at its worst...
My scalp psoriasis is currently out of control I currently use Ketopine shampoo but it doesn't seem to be working at the minute if anything making it worse. I was just wondering people's views on tar shampoo and if someone could explain how the shampoos work, and any tips or advice on controlling the flakes although at the minute there more like bits. I have to tie my hair back to cover it but its not wlenoygh at the minute :(
Posted by: Fred - Fri-03-05-2013 09:30 AM
- No Replies
Many people weigh themselves and track what they eat, but neurobiology professor Russell Poldrack studies himself in an in-depth way no one has done before in his quest to learn how a healthy brain functions daily.
His study consists of a weekly blood sample and two MRI scans per week paired with mood questionnaires, according to Poldrack. Poldrack said he also completes daily surveys measuring aspects such as sleep quality, diet and what happened that day. Poldrack said he began data collection in September 2012 and plans to publish his results in the fall.
Poldrack said he tracks the fluctuations of his psoriasis and has found that on days he recorded it being worse, the genes related to psoriasis are expressed more.
“Even though this is really preliminary, it starts to show us the kinds of stuff that we might be able to find,” Poldrack said. “The question is if we had enough data could we relate this back to brain function, too.”
There is no research on how brains change over a period of weeks and months, and because some disorders, including depression, fluctuate over this period, people with these disorders could get scanned regularly to measure which treatments work, Poldrack said.
One of Poldrack’s colleagues, Tom Schonberg, said that his research receives some criticism. “His colleagues try to plant the seeds of doubt and criticism all the time because when it’s out there scientifically, when he reaches the stage of trying to publish this, he’ll get criticism from all directions,” Schonberg said.
Poldrack said although it will be challenging to find people willing to participate, he wants to do the study on a large set of people. Poldrack said he may not have the funds to analyze a year’s worth of blood samples, which show how gene levels relate to what is happening in the body, because it costs $700 to analyze a week’s worth of blood.
“If we could find the money … then we could go back and do it,” Poldrack said. “It would be a really unique data set. I don’t know of any other data sets of a person who collected blood at the same time every week for such a long period of time.”
Posted by: Fred - Wed-01-05-2013 15:19 PM
- No Replies
Attorney General Eric T. Schneiderman announced today that New York along with 35 other states reached an $11 million settlement with the drug manufacturer Amgen, Inc. The agreement resolves claims that the company inflated pricing data for six of its prescription drugs in a way that caused New York and the other settling states’ Medicaid programs to overpay for those drugs.
“There are no excuses for ripping off New York State taxpayers and defrauding our Medicaid programs,” Attorney General Schneidermansaid.“At a time when state budgets are already strained, I am committed to going after any company that rips off our taxpayers-no matter how big they are.With this settlement the message we are sending is clear: Biotechnology giants are not above the law and my office will continue to ensure that those who cheat the system are held accountable.”
The drug pricing data at issue in this settlement concerns the “Average Wholesale Price” (AWP) and “Wholesale Acquisition Cost” (WAC), benchmarks used by most states’ Medicaid programs, including New York, to set pharmacy reimbursement rates for pharmaceuticals dispensed to state Medicaid beneficiaries.New York and the 35 other states alleged that Amgen reported inflated AWP and WAC pricing data, thereby creating an artificially inflated “spread” between the price at which Medicaid providers dispensed the named drugs and the price at which the states reimbursed providers for the drugs. After creating the inflated spread, Amgen marketed that spread to Medicaid providers in order to boost Amgen’s sales of Aranesp, Enbrel, Epogen, Neulasta, Neupogen, and Sensipar.
This settlement was part of a larger investigation into allegations of illegal marketing practices, which included promoting the drugs for unapproved uses, and illegal kickbacks schemes by Amgen. The investigation resulted in a misdemeanor guilty plea in federal court by Amgen for introducing a misbranded drug into interstate commerce. The company has now paid a total of more than $647 million in damages related to the investigations, with New York’s Medicaid program recovering over $19.2 million of the money.
New York’s recovery pursuant to this national, multi-state settlement is $3.3 million.
In this instance, as in the previous settlements, New York lead a national team made up of state attorneys and analysts from California, Illinois, Indiana and North Carolina and worked through the National Association of Medicaid Fraud Control Units.
The New York team was headed up by Jay Speers, Counsel to the New York MFCU; Carolyn Ellis, Special Assistant Attorney General; Michael LaCasse, Chief Auditor for MFCU’s Civil Enforcement Division; Meghan Collins, Associate Special Auditor Investigator; Matthew Tandle, Senior Special Auditor Investigator; Karin Flynn, Associate Special Auditor Investigator; Colin Ware, Special Auditor Investigator and Nicholas Furnari, Computer Programmer Analyst. The team was supervised by Deputy Attorney General Monica Hickey-Martin, Director of the Medicaid Fraud Control Unit, and Executive Deputy Attorney General for Criminal Justice Kelly Donovan.
Posted by: Fred - Tue-30-04-2013 19:52 PM
- No Replies
Ipsos Healthcare, the global healthcare division of Ipsos, has announced the launch of Ipsos Healthcare SEES (Syndicated Expert Ethnographic Studies). The disease-specific studies will bring to life the day-to-day challenges of living with a chronic disease.
Beginning with Psoriatic Arthritis (SEES PsA), the studies will reveal the patient perspective in 3 core areas: quality of life (lifestyle, coping mechanisms); medication (regimen, tolerance, compliance); and pathway to diagnosis (HCP interaction, time lapse). Initially available in the UK, France, Italy, Spain and the US, they will be delivered in collaboration between the disease experts from Ipsos Healthcare’s Global Therapy Monitors teams, and the anthropologically-trained researchers from Ipsos’ Ethnography Centre of Excellence.
Ipsos Healthcare SEES brings together the patient perspective offered by ethnography with the Global Therapy Monitors’ quantitative view of the market and physician perceptions; in doing so, it can help pharmaceutical and biotech companies identify wider patient-level and market opportunities. Subscribers will gain ongoing understanding through access to a searchable database of patient video footage, in addition to customised reports.
Commented Rhoda Schmuecking, President of Global Therapy Monitors, Ipsos Healthcare:
“Living with a chronic disease means constantly adapting to all aspects of life. Ipsos Healthcare SEES can help us to understand patients’ needs and motivations for seeking treatment, their true compliance versus stated levels, and the involvement of patients in their treatment decisions. This understanding can guide every articulation of a pharmaceutical or biotech company’s product value, from doctor detailing and conference material to employee education and patient support.”
Added Victoria Guyatt, Deputy Head of Ethnography, Ipsos UU:
“Ultimately, ethnography has the power to change the way the pharma / biotech industry views patients, putting them at the centre of decision-making.”
*Ipsos is a global independent market research company ranking third worldwide among research firms. They specialize in six areas: advertising research; marketing research; media, content and technology research; loyalty, quality and customer relationship management research; opinion polls and social research; and survey management, data collection and delivery.
Posted by: Fred - Mon-29-04-2013 22:14 PM
- No Replies
This study published in The British Journal of Dermatology suggests clinicians should avoid intermittent treatment with Infliximab (Remicade) for psoriasis.
Continuous maintenance therapy with infliximab 5 mg/kg every 8 weeks is effective for moderate-to-severe plaque-type psoriasis.
This study evaluated efficacy and safety of continuous versus intermittent infliximab maintenance therapy.
RESTORE2 was a long-term extension of RESTORE1. At baseline of RESTORE2, eligible patients who had received infliximab for 26 weeks and achieved Psoriasis Area and Severity Index (PASI) 75 in RESTORE1 were re-randomised 1:1 to continuous therapy (infliximab 5 mg/kg every 8 weeks) or intermittent therapy (no infliximab until >50% loss of PASI improvement). Safety and efficacy assessments occurred throughout the study.
222 patients were randomised to receive continuous therapy; 219 to intermittent therapy. Numerically more serious infusion-related reactions occurred with intermittent therapy (8/219 patients, 4%) than continuous therapy (1/222 patients, <1%), leading the sponsor to terminate the study. Mean duration of exposure to infliximab was 40.12 weeks (SD = 27.55,) with a mean of 5.8 infusions (range, 0–16) for continuous therapy and 22.78 weeks (SD = 22.98) with a mean of 3.4 infusions (range, 0–16) for intermittent therapy. Although no formal efficacy analyses were conducted, continuous therapy led to numerically greater PASI 75 at week 52 in the continuous group (81/101, 80%) than in the intermittent group (39/83, 47%); several other efficacy measures demonstrated similar patterns.
For patients with moderate-to-severe plaque-type psoriasis, continuous therapy with infliximab may be more effective than intermittent therapy. The incidence of serious infusion-related reactions in the intermittent group suggests that clinicians should avoid intermittent therapy in this population.
Posted by: Fred - Mon-29-04-2013 19:29 PM
- No Replies
Do you, or have you used Oat Baths to help with psoriasis? If so Outline productions would like to hear from you for their new ground-breaking programme exploring the world of alternative medicine, health and beauty.
They are looking for people who are using an unusual homemade remedy for health and beauty purposes. Across the nation, people are taking health and beauty matters into their own hands. More and more people are treating themselves at home, using all sorts of regular household products in unexpected ways to try and treat ailments or boost their wellbeing.
They are particularly interested in talking with psoriasis patients who use or have used oat baths as a successful treatment for psoriasis.
If you do use this treatment and would like to chat further, you can talk to Sam from Outline Productions on 02074247626 or email email@example.com
Please mention Psoriasis Club, and feel free to post on this thread how you got on.
I'm about to start taking ciclosporine for moderate/severe guttate psoriasis. Recreational drugs (in moderation) have never had too bad effects on my psoriasis. I'm really worried that certain ones might have an interaction with ciclosporine, and I cant find any information anywhere. I'm about to finish my degree and really dont want to have to worry about what I'm putting into my body for just two weeks, so I was wondering if anyone on here could help.
Sorry if I've offended anyone.
Posted by: Fred - Fri-26-04-2013 13:33 PM
- No Replies
Chronic plaque psoriasis is frequently associated with metabolic disorders including obesity. Antitumour necrosis factor α treatments can induce body-weight increase in patients with psoriasis. Information on the effect of ustekinumab (Stelara) on body weight is not available.
To investigate whether therapy with ustekinumab (Stelara) is associated with changes in body mass index (BMI) in patients with chronic plaque psoriasis.
A prospective, multicentre study comparing the changes in BMI in two closed cohorts of patients with psoriasis during 7-month treatment with ustekinumab (Stelara) (n = 79) or infliximab (Remicade) (n = 83).
Patients treated for 7 months with infliximab (Remicade) showed a significant (P < 0·001) increase in mean BMI (2·1 ± 4·5%) and body weight (2·5 ± 3·3 kg) compared with patients treated with ustekinumab (Stelara) (0·1 ± 3·3%; 0·6 ± 1·1 kg). Some 45% of patients treated with infliximab (Remicade) had a BMI increase > 2%, compared with only 11% of those receiving ustekinumab (Stelara) (P = 0·01). In the multivariate analysis, all other clinical parameters predicted the BMI increase, except for the use of infliximab (Remicade). At month 7, 96% of patients treated with infliximab (Remicade) and 82% of patients treated with ustekinumab (Stelara) achieved at least a 50% improvement from their baseline psoriasis area and severity index (PASI 50), and 69% of the infliximab (Remicade) group compared with 58% of the ustekinumab (Stelara) group achieved at least PASI 75. There was no difference in the proportion of PASI 50 and PASI 75 responders between the two groups.
In contrast to infliximab (Remicade), ustekinumab (Stelara) does not increase BMI in patients with chronic plaque psoriasis. This difference could be taken into account in the selection of biologics when treating patients with psoriasis.
Damn and I thought I could blame Stelara for my weight increase.
Posted by: Fred - Fri-26-04-2013 13:23 PM
- No Replies
Nail psoriasis is common in patients with psoriasis and can seriously affect their quality of life. Current treatments are limited and there is no standard course of therapy.
To assess the efficacy and safety of etanercept (Enbrel) on nail psoriasis in patients with moderate-to-severe psoriasis.
Patients with moderate-to-severe plaque psoriasis, who had previously failed at least one form of systemic therapy for nail psoriasis, were randomized to receive open-label Enbrel 50 mg twice weekly (BIW) for 12 weeks followed by once weekly (QW) for 12 weeks (BIW/QW group) or Enbrel 50 mg QW for 24 weeks (QW/QW group). The primary endpoint was the mean improvement in the Nail Psoriasis Severity Index (NAPSI; score range 0–8) over 24 weeks in the target fingernail with the most severe abnormalities.
Seventy-two patients received one or more doses of Enbrel (38 BIW/QW; 34 QW/QW) and 69 patients were included in the modified intent-to-treat population. At baseline, mean (standard error) target fingernail NAPSI score was 6·0 (0·3) in the BIW/QW group and 5·8 (0·3) in the QW/QW group. At week 24, mean target fingernail NAPSI score had decreased significantly by −4·3 [95% confidence interval (CI) −4·9 to −3·7; P < 0·0001] in the BIW/QW group and by −4·4 (95% CI −5·0 to −3·7; P < 0·0001) in the QW/QW group. Improvement in NAPSI showed significant correlation with Psoriasis Area and Severity Index improvement. Enbrel was well tolerated with no unexpected safety findings.
Both Enbrel regimens were effective at treating nail psoriasis in this patient population.
Posted by: Fred - Fri-26-04-2013 13:14 PM
- No Replies
Before starting an anti-TNF treatment for psoriasis patients should always have a TB test. This study compared the different tests available, (TST) tuberculin skin test, (QFR) QuantiFERON®-TB Gold In-Tube, and (TSTB) T-SPOT.TB.
Targeted biological therapies have transformed the treatment of chronic inflammatory disease. However, reactivation of latent tuberculosis infection (LTBI) is a significant risk with the use of antitumour necrosis factor (anti-TNF)-α therapy and screening is mandatory prior to treatment. The tuberculin skin test (TST) may be difficult to interpret in patients with inflammatory disease or receiving immunosuppressive therapies.
The aim of this study was to evaluate and compare the QuantiFERON®-TB Gold In-Tube (QFR) and T-SPOT.TB (TSTB) interferon-γ-release assays (IGRA) against the TST in a cohort of patients commencing anti-TNF-α therapies for chronic inflammatory disease.
A prospective cross-sectional study was undertaken at a London tertiary referral centre. Demographic data collected included TB risk factors. TST, QFR and TSTB were performed in all patients.
Seventy patients with chronic plaque psoriasis were included in the study. Agreement between QFR and TSTB, excluding indeterminate results, was 89% (κ = 0·567), between QFR and TST 85% (κ = 0·313) and 81% (κ = 0·244) between TSTB and TST. There was no significant association with concomitant immunosuppression and either TST or IGRA results. Seven patients received chemoprophylaxis for LTBI diagnosed after clinical risk assessment together with positive TST and/or IGRA. Three patients had positive results in all three tests.
While there was moderate overall agreement between QFR and TSTB and fair correlation between TST, QFR and TSTB, there were a number of discordant results, suggesting that a three-pronged approach using TST, QFR and TSTB may be of additional benefit.
Posted by: Fred - Fri-26-04-2013 12:59 PM
- No Replies
Ustekinumab (Stelara) is a fully human anti-p40 monoclonal antibody which neutralizes interleukin (IL)-12 and IL-23, thereby interfering with T-helper (Th)1/Th17 pathways and keratinocyte activation, and is highly effective in the treatment of psoriasis. During ustekinumab treatment, some of our patients noticed reduced koebnerization of noninvolved skin and less new plaque formation.
To determine whether ustekinumab improves psoriasis-related gene expression and tape-strip responses in noninvolved skin.
Before and 4 weeks after ustekinumab treatment, noninvolved skin was tape-stripped. After 5 h, biopsies were taken from untouched and tape-stripped skin. The mRNA expression of psoriasis-related markers such as NGF, GATA3 and IL-22RA1, and several antimicrobial peptides (AMP) was quantified. Leucocyte counts and a broad range of inflammatory serum proteins were analysed to gain insight into the systemic alterations.
Four weeks following a single ustekinumab injection, NGF showed a significant decrease, whereas GATA3 and IL-22RA1 expression increased, indicative of reduced responsiveness to epidermal triggering. This was accompanied by an increase of the inflammation-related serum proteins GPNMB, MST1 and TRADD. The baseline and tape-strip-induced mRNA expression of the AMP human β-defensin-2 (hBD-2), S100A7 and LL-37 remained unaltered. Clinically, after 4 weeks, eight out of 11 patients showed a 50% psoriasis area and severity index (PASI) improvement, which was accompanied by a significant reduction in serum hBD-2 levels. No changes were noted in total leucocytes, C-reactive protein and erythrocyte sedimentation rate.
These findings indicate that ustekinumab reduces psoriasis-related gene expression in noninvolved psoriatic skin, making it more resistant to exogenous triggering, without disturbing its antimicrobial response. In parallel, ustekinumab modulates important circulating inflammation-related proteins.
Posted by: Fred - Fri-26-04-2013 12:51 PM
- No Replies
Psoriasis is a chronic, inflammatory skin condition associated with a high frequency of cardiovascular events. Modifications of plasma lipids, and an increase in the levels of biochemical markers of inflammation and lipid peroxidation have been reported in subjects with psoriasis, suggesting a relationship between psoriasis, inflammation and oxidative damage.
To investigate whether modulation of inflammatory activity by tumour necrosis factor-α inhibitors in patients with psoriasis is associated with modification of lipid profiles, oxidative stress and paraoxonase (PON)1 activity.
The levels of plasma lipids and lipoprotein(a), and the levels of the markers of inflammation and lipid peroxidation were evaluated in subjects with psoriasis (n = 23) before and after 24 weeks of treatment with etanercept (Enbrel). In the same subjects plasma total antioxidant capacity and the activity of PON1, an antioxidant and anti-inflammatory enzyme associated with the high-density lipoproteins (HDLs), were investigated.
The results showed that clinical improvement in patients with psoriasis treated with etanercept (Enbrel) is associated with a reduction in the levels of inflammatory markers [C-reactive protein (CRP)] and lipid peroxidation, and also with increased antioxidant capacity in the serum of patients with psoriasis. These modifications are associated with a significant increase in the activity of PON1. A significant increase in the PON1/CRP ratio has also been observed in patients with psoriasis after treatment. The significant inverse correlation between CRP and PON1 activity suggests a relationship between PON1 activity and inflammation.
Treatment with etanercept (Enbrel)is associated with a reduction in lipid peroxidation and an improvement in HDL antioxidant and anti-inflammatory properties.
* Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage and can cause disruptions in normal mechanisms of cellular signalling.